ABHD17 enzymes regulate dynamic plasma membrane palmitoylation and N-Ras-dependent cancer growth
J. R. Remsberg, R. M. Suciu, N. A. Zambetti, T. W. Hanigan, A. J. Firestone, A. Inguva, A. Long, N. Ngo, K. M. Lum, C. L. Henry, S. K. Richardson, M. Predovic, B. Huang, A. R. Howell, M. J. Niphakis, , B. F. Cravatt
This study identifies ABD957, a selective ABHD17 inhibitor, which disrupts N-Ras depalmitoylation and inhibits NRAS-mutant AML growth, suggesting potential as a targeted therapy.
bioRxiv · May 21, 2020Cancer Biology